Abstract:Non-alcoholic fatty liver disease (NAFLD) was recently renamed to metabolic dysfunctionassociated liver disease (MASLD) to emphasize the metabolic dysfunctions that most often accompany its manifestation [1]. MASLD covers a spectrum of liver diseases, ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), a clinical condition characterized by steatosis, hepatocellular injury, and inflammation with or without fibrosis [1]. MASH can further progress to cirrhosis and, in a certain fraction of patients, to hepatocellular carcinoma (HCC) [2]. Multiple factors sustain the transition from MASLD to MASH and its advanced stages, but emerging evidence indicates chronic inflammation as the driving force underlying the process [2]. Therefore, understanding the cellular and molecular mechanisms responsible for inflammatory responses may lay the foundations for treatments to counteract MASH and its complications.In this article collection, the authors summarized the recent advances concerning the modulation of inflammatory responses associated with MASH.Growing evidence indicates that hepatokines mediate key steps of MASLD/MASH [3,4]. Foglia and colleagues addressed this issue by exploring the pathological implications of the histidine-rich glycoprotein (HRG) in MASH-related carcinogenesis. HGR is a glycoprotein which interacts with several molecules and modulates essential biological processes [5]. The authors found that HRG levels increase in parallel with the disease severity, and the HRG genetic deletion protects mice from MASH-related HCC by a ecting multiple pathways.Hepatokines, like other molecules, mediate biological e ects by triggering specific receptors, which transduce complex signals underlying MASH [6]. Apostolo et al. reviewed the implications of TAM receptors (Tyro 3, Axl and MerTK) in the transition from MASLD/MASH to HCC. The authors described that TAM receptors, along with the common ligand Growth Arrest Specific (GAS) 6, support the development of MASH. Indeed, the Gas6/TAM axis modulates inflammatory responses and stimulates the activation, survival and proliferation of hepatic stellate cells (HSCs). The TAM/Gas6 system also promotes the induction of signalling pathways involved in tumour growth and dissemination. Furthermore, it may lead to resistance to sorafenib in HCC cells, so much so that pharmacological targeting of Axl restores the cell sensitivity to sorafenib. Grøndal et al. further investigates TAM receptors in MASH, observing that the levels of the soluble form of Axl (sAxl) increase in preclinical models of MASLD/MASH, in parallel with the induction of inflammatory responses, suggesting that sAxl may represent an early marker for MASLD/MASH. The authors also described the mechanistic involvement of Axl in MASLD/MASH, reporting that its pharmacological inhibition reduces steatosis, inflammation and fibrosis. The authors also investigated the mechanisms by which Axl inhibition ameliorates MASLD/MASH, describing that Axl inhibition has an immunomodulatory action by lowering the hepatic expression of pro-inflammatory mediators along with the abundance of NK cells and various dendritic cell (DC) subsets.Besides TAM, additional families of receptors contribute to inflammatory responses like protease-activated receptors (PARs). PARs are the substrate of multiple proteases capable of cutting the extracellular N-terminus sequence, which becomes the agonist of PARs themselves [7]. Villano and Pontisso reviewed the current available data on PAR2 and its implications in MASLD/MASH. PAR2 activation drives MASLD development by impairing the insulin pathway and causing insulin resistance (IR) and liver steatosis. PAR2 also promotes the transition from MASLD to MASH by activating inflammatory pathways and HSCs. PAR2 activation also supports cell transformation by inhibiting the AMPK-mediated autophagy and promotes tumour growth and metastatization via the PI3K/AKT signaling pathway. Consistently, PAR2 antagonists inhibit liver injury, inflammation and fibrosis in the experimental MASH.MASH-associated inflammatory responses involve multiple immune cell subsets belonging to the innate and adaptive immunity branches, such as macrophages (MFs), dendritic cells (DCs), NK/NKT cells and T/B-lymphocytes [8][9][10]. These cells influence the hepatic microenvironment by secreting multiple cyto/chemokines and mediating the disease progression [11]. Saueret al. analyzed this issue by investigating the e ects of the secretome derived from di erentially polarized human primary monocytes/macrophages and NK cells in activating HSCs. The authors found that "classical" stimuli for MFs (TNF-α, IL-4 and IL13) and NK cells (IL-15) fail in activating HSCs in vitro. Conversely, the hyperactivation of MFs and NK cells with the phorbol 12-myristate 13-acetate (PMA), a non-specific pro-inflammatory agent, promotes a strong activation of HSCs. O -Abstract Truncated-

Hepatic danger signaling triggers TREM2 + macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation

Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis

Myeloid Trem2 Ameliorates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease by Regulating Macrophage Pyroptosis and Inflammation Resolution

Prolonged Hypernutrition Impairs TREM2-dependent Efferocytosis to License Chronic Liver Inflammation and NASH Development.

Egr2 drives the differentiation of Ly6C hi monocytes into fibrosis-promoting macrophages in metabolic dysfunction-associated steatohepatitis in mice

Myeloid‐Mas Signaling Modulates Pathogenic Crosstalk among MYC+CD63+ Endothelial Cells, MMP12+ Macrophages, and Monocytes in Acetaminophen‐Induced Liver Injury

Effect of triggering receptor expressed on myeloid cells 2-associated alterations on lipid metabolism in macrophages in the development of non-alcoholic fatty liver disease

Hepatic NLRP3-Derived Hsp70 Binding to TLR4 Mediates MASLD to MASH Progression upon Inhibition of PP2A by Harmful Algal Bloom Toxin Microcystin, a Second Hit

Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy

Editorial: Inflammatory responses on the road from NASH to HCC: pathogenic mechanisms and possible therapeutic strategies

Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2

METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression

Myeloid Trem2 Orchestrates Nonalcoholic Steatohepatitis-Associated Inflammation and HCC Progression by Reprogramming Recruited Macrophages

YAP activation in liver macrophages via depletion of MST1/MST2 enhances liver inflammation and fibrosis in MASLD

Macrophage-Hepatocyte Circuits Mediated by Grancalcin Aggravate the Progression of Metabolic Dysfunction Associated Steatohepatitis

Signaling through the nicotinic acetylcholine receptor in the liver protects against the development of metabolic dysfunction-associated steatohepatitis

TREM2 protects against inflammation by regulating the release of mito-DAMPs from hepatocytes during liver fibrosis

NUAK1 promotes metabolic dysfunction-associated steatohepatitis progression by activating Caspase 6–driven pyroptosis and inflammation

E2F2 Reprograms Macrophage Function By Modulating Material and Energy Metabolism in the Progression of Metabolic Dysfunction‐Associated Steatohepatitis

GSDME promotes MASLD by regulating pyroptosis, Drp1 citrullination-dependent mitochondrial dynamic, and energy balance in intestine and liver

Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning